Video
Author(s):
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).
Shah states that his first choice for patients with p53-mutated MCL is lenalidomide (Revlimid).
Additionally, Shah says that the next big biomarker will focus on minimal residual disease, as it has been shown to predict for relapse down the line.